hepatitis-c

Documents about hepatitis-c

• Long Term Follow up of Chronic HCV Patients Receiving DAAS#888297ClinicalTrials.gov
• Hepatitis c virus infection risk tool for patients with cancer#1039226IRIS
• Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023.#281631Repisalud
• Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.#807833ClinicalTrials.gov
• The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients#859345ClinicalTrials.gov
• Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)#878599ClinicalTrials.gov
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy#876736ClinicalTrials.gov
• Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis#805928ClinicalTrials.gov
• Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China#20384DOAJ
• Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4#854324ClinicalTrials.gov
• Clinical Impacts of Achieving SVR in Patients With Advanced Hepatic Fibrosis Related to Chronic HCV Treated With Direct Acting Antivirals#861368ClinicalTrials.gov
• A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)#888427ClinicalTrials.gov
• Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort."#891973ClinicalTrials.gov
• Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection#835662ClinicalTrials.gov
• Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection#838401ClinicalTrials.gov
• Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus#121923HAL (France)
• Digital Community to Improve Health in Rural Areas#174951ClinicalTrials.gov
• Patient-Centered Hepatitis C Virus Care for People Who Inject Drugs—The HERO Study#213679NCBI Bookshelf
• Primary Prevention Hepatocellular Carcinoma by Metformin#474895ClinicalTrials.gov
• Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.#864903ClinicalTrials.gov
• Biomarkers of Liver Fibrosis#870054ClinicalTrials.gov
• Study of Drug Combination on Pharmacokinetics in Healthy Volunteers#1007083ClinicalTrials.gov
• An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease#806353ClinicalTrials.gov
• Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus#908489ClinicalTrials.gov
• Evaluation of the Safety and Effectiveness of Direct-acting Antiviral Drugs in the Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease: National Multicenter Study#912569ClinicalTrials.gov
• Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom)#980126ClinicalTrials.gov
• Peer support boosted Hepatitis C treatment access among marginalised populations in England: A Bayesian causal factor analysis.#214804bioRxiv / medRxiv
• A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals#858155ClinicalTrials.gov
• Prevalence and risk factors of hepatitis B, hepatitis C, and syphilis among reproductive-age adults in the Tigray region, Northern Ethiopia: a community-based cross-sectional study.#236377NCBI PubMed Central
• Observational Study of the Interaction Between Hepatitis C Virus Infection and Pregnancy#831051ClinicalTrials.gov
• Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment#893469ClinicalTrials.gov
• IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1#902224ClinicalTrials.gov
• Telaprevir in Genotype 3 HCV#980123ClinicalTrials.gov
• Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin#868500ClinicalTrials.gov
• The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)#874209ClinicalTrials.gov
• Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).#993944ClinicalTrials.gov
• Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection#864996ClinicalTrials.gov
• Screening Program for Asymptomatic Hepatitis C: Uptake and Detection in the Marche Region of Italy.#140656NCBI PubMed Central
• The Use of Human Liver Chimeric Mice to Study Hepatitis C Virus Antibody Escape: Implications for Vaccine Development#295598PubMed Central
• Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)#966746ClinicalTrials.gov
• A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection#846833ClinicalTrials.gov
• Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection#909636ClinicalTrials.gov
• REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy#911425ClinicalTrials.gov
• A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study#993049ClinicalTrials.gov
• Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment#1010455ClinicalTrials.gov
• Hepatitis C: how has France limited the expenses related to new treatments?#168465HAL (France)
• Hepatitis C Micro-Elimination in a Deprived Coastal Town: Lessons From Blackpool.#446361NCBI PubMed Central
• A Drug-drug Interaction Study Between Daclatasvir and Metformin#471440ClinicalTrials.gov
• Hepatitis C Virus (HCV) Positive Kidney Grafts in HCV Negative Recipients#829722ClinicalTrials.gov
• A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.#870189ClinicalTrials.gov